Clinical Trial Update: Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial [Phase 3]

View source ↗

Summary

Phase 3 ZESCA trial evaluating Zyban (bupropion) as a smoking cessation aid in patients after acute coronary syndrome. Results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction

Drugs mentioned

• Zyban (bupropion)

Snippet

Sponsor: Mark Eisenberg | Conditions: Acute Coronary Syndrome, Myocardial Infarction | Phase 3 | Status: COMPLETED | Results posted: 2015-04-23